<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1501">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05141617</url>
  </required_header>
  <id_info>
    <org_study_id>PLAEGV-TRE</org_study_id>
    <nct_id>NCT05141617</nct_id>
  </id_info>
  <brief_title>Management of Oxaliplatin-related Gastroesophageal Variceal Bleeding</brief_title>
  <official_title>Endoscopic Treatment vs Transjugular Intrahepatic Portosystemic Shunt in the Management of Oxaliplatin Related Gastroesophageal Variceal Bleeding: A Multicenter, Randomized, Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>First Affiliated Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Minhang Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anhui Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this randomized controlled study, we aim to compare the efficacy and safety of these two&#xD;
      interventions in patients with oxaliplatin-induced gastroesophageal variceal bleeding.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oxaliplatin is used as the first-line chemotherapy for colorectal cancer. However,&#xD;
      oxaliplatin-induced hepatotoxicity could lead to sinusoidal injury and portal hypertension in&#xD;
      the long term. Variceal bleeding, as the most common complication of portal hypertension,&#xD;
      threaten these patents' life. Endoscopic treatment and Transjugular Intrahepatic&#xD;
      Portosystemic Shunt (TIPS) are both recommended management of gastroesophageal variceal&#xD;
      bleeding. In this randomized controlled study, we aim to compare the efficacy and safety of&#xD;
      these two interventions in patients with oxaliplatin-induced gastroesophageal variceal&#xD;
      bleeding.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 3, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24-week re-bleeding</measure>
    <time_frame>24 weeks</time_frame>
    <description>Hematemesis ,melena, or hemoglobin level decreased by 10 g/L within 6 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>8-week re-bleeding</measure>
    <time_frame>8 weeks</time_frame>
    <description>Hematemesis ,melena, or hemoglobin level decreased by 10 g/L within 6 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>8-week mortality</measure>
    <time_frame>8 weeks</time_frame>
    <description>death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>8-week adverse events</measure>
    <time_frame>8 weeks</time_frame>
    <description>Other complications of portal hypertension such as the progression of ascites, liver failure, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-week mortality</measure>
    <time_frame>24 weeks</time_frame>
    <description>death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-week adverse events</measure>
    <time_frame>24 weeks</time_frame>
    <description>Other complications of portal hypertension such as the progression of ascites, liver failure, etc.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Gastroesophageal Varices Hemorrhage</condition>
  <condition>Gastrointestinal Cancer</condition>
  <condition>Received Oxaliplatin-based Chemotherapy</condition>
  <arm_group>
    <arm_group_label>Endoscopic treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the endoscopic treatment group receive endoscopic variceal ligation and N-butyl-cyanoacrylate according to the type of varices.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIPS group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the TIPS group receive transjugular intrahepatic portosystem stent-shunt.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic treatment</intervention_name>
    <description>Patients in the endoscopic treatment receive endoscopic variceal ligation and N-butyl-cyanoacrylate according to the type of varices</description>
    <arm_group_label>Endoscopic treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TIPS</intervention_name>
    <description>Patients in the TIPS group receive Transjugular Intrahepatic Portosystemic Shunt</description>
    <arm_group_label>TIPS group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Having received oxaliplatin-based chemotherapy for at least one cycle&#xD;
&#xD;
          2. History of variceal bleeding (including hematemesis or melena)&#xD;
&#xD;
          3. Portal hypertension confirmed by CT or MRI&#xD;
&#xD;
          4. Esophageal and / or gastric varices confirmed by endoscopy&#xD;
&#xD;
          5. Informed consent signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. With serious life-threatening diseases of circulation / blood / respiratory system&#xD;
&#xD;
          2. With known causes of liver cirrhosis (hepatitis B, hepatitis C, autoimmune,&#xD;
             schistosomiasis, non-alcoholic fatty liver disease, and etc.)&#xD;
&#xD;
          3. With contraindications of endoscopic treatments and TIPS;&#xD;
&#xD;
          4. Participation refused&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shiyao CHENCHEN, M.D. &amp; Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaoquan HUANG, M.D.</last_name>
    <phone>008618801733835</phone>
    <email>huang.xiaoquan@zs-hospital.sh.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Gastroenterology and Hepatology</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoquan HUANG</last_name>
      <phone>008618801733835</phone>
      <email>huang.xiaoquan@zs-hospital.sh.cn</email>
    </contact>
    <investigator>
      <last_name>Shiyao CHEN</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiaoquan HUANG</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Liyuan NI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Huang X, Li F, Wang L, Xiao M, Ni L, Jiang S, Ji Y, Zhang C, Zhang W, Wang J, Chen S. Endoscopic treatment of gastroesophageal variceal bleeding after oxaliplatin-based chemotherapy in patients with colorectal cancer. Endoscopy. 2020 Sep;52(9):727-735. doi: 10.1055/a-1157-8611. Epub 2020 May 7.</citation>
    <PMID>32380558</PMID>
  </results_reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 1, 2021</study_first_submitted>
  <study_first_submitted_qc>November 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2021</study_first_posted>
  <last_update_submitted>November 20, 2021</last_update_submitted>
  <last_update_submitted_qc>November 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Zhongshan Hospital</investigator_affiliation>
    <investigator_full_name>Shiyao Chen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>portal hypertension</keyword>
  <keyword>Gastrointestinal Cancer</keyword>
  <keyword>oxaliplatin</keyword>
  <keyword>gastroesophageal variceal bleeding</keyword>
  <keyword>endoscopic treatment</keyword>
  <keyword>Transjugular Intrahepatic Portosystemic Shunt</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

